Clinical trial
A Double-blind, Randomized, Placebo-controlled and Active-comparator-controlled Phase 2b Study to Evaluate Statin-associated Myalgia Incidence, Lipid Profile Effect, and Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients With Primary Hypercholesterolemia, Fredrickson IIa or IIb, Who Have Discontinued Two or More Prior Statin Therapies Due to Statin-associated Myalgia
NCT01279590 is registered in ClinicalTrials.gov with Furiex Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Placebo-controlled and Active-comparator-controlled Phase 2b Study to Evaluate Statin-associated Myalgia Incidence, Lipid Profile Effect, and Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients With Primary Hypercholesterolemia, Fredrickson IIa or IIb, Who Have Discontinued Two or More Prior Statin Therapies Due to Statin-associated Myalgia
- Lead sponsor
- Furiex Pharmaceuticals, Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2011
- Completion date
- November 30, 2011
- Enrollment
- 282 (actual)
- Sites
- 67
Conditions
As the registry lists them; a condition with its own page is linked.
hypercholesterolemia, hyperlipidemia, myalgia